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ABSTRACT Bordetella filamentous hemagglutinin (FHA), a primary component of acellular pertussis vaccines, contributes to
virulence, but how it functions mechanistically is unclear. FHA is first synthesized as an ~370-kDa preproprotein called FhaB.
Removal of an N-terminal signal peptide and a large C-terminal prodomain (PD) during secretion results in “mature” ~250-kDa
FHA, which has been assumed to be the biologically active form of the protein. Deletion of two C-terminal subdomains of FhaB
did not affect production of functional FHA, and the mutant strains were indistinguishable from wild-type bacteria for their
ability to adhere to the lower respiratory tract and to suppress inflammation in the lungs of mice. However, the mutant strains,
which produced altered FhaB molecules, were eliminated from the lower respiratory tract much faster than wild-type B. bron-
chiseptica, suggesting a defect in resistance to early immune-mediated clearance. Our results revealed, unexpectedly, that full-
length FhaB plays a critical role in B. bronchiseptica persistence in the lower respiratory tract.
IMPORTANCE The Bordetella filamentous hemagglutinin (FHA) is a primary component of the acellular pertussis vaccine and an
important virulence factor. FHA is initially produced as a large protein that is processed during secretion to the bacterial surface.
As with most processed proteins, the mature form of FHA has been assumed to be the functional form of the protein. However,
our results indicate that the full-length form plays an essential role in virulence in vivo. Furthermore, we have found that FHA
contains intramolecular regulators of processing and that this control of processing is integral to its virulence activities. This
report highlights the advantage of studying protein maturation and function simultaneously, as a role for the full-length form of
FHA was evident only from in vivo infection studies and not from in vitro studies on the production or maturation of FHA or
even from in vitro virulence-associated activity assays.
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Two-partner secretion (TPS) is a widespread protein secretionpathway for Gram-negative bacteria in which a large exopro-
tein (generically called TpsA) is translocated through a cognate
outer membrane -barrel pore protein (TpsB) to the bacterial
surface, where the exoprotein is then able to interact with its en-
vironment. The mechanism by which this occurs is complex, with
fundamental aspects of the process, such as how unidirectional
protein translocation across a membrane is achieved in the ab-
sence of chemical energy and how these massive proteins are able
to fold correctly in the absence of typical quality control mecha-
nisms, remaining unclear. Virulence functions have been attrib-
uted to most TPS systems and include adherence to host tissues (1,
2), iron acquisition (3), cytotoxicity (4, 5), and immune evasion
(6), which contribute to bacterial colonization and persistence.
Whooping cough, or pertussis, is currently reemerging in the
United States and other developed countries. Increased incidence
in recent years has coincided with a switch from whole-cell per-
tussis (wP) vaccines to acellular pertussis (aP) vaccines that dis-
play reduced reactogenicity (7). Pertussis is primarily caused by
the human-restricted Gram-negative pathogen Bordetella pertus-
sis, and aP vaccines typically consist of three to five proteins that it
secretes: filamentous hemagglutinin (FHA), pertussis toxin (Ptx),
pertactin (Prn), and, often, fimbrial subunits (Fim2 and Fim3).
While the underlying reasons are not completely understood, the
recent surge in pertussis incidence is likely largely due to deficien-
cies in aP vaccine efficacy, including induction of relatively short-
lived immunity and inability to prevent colonization and trans-
mission (8–11). Despite decades of research, our understanding of
the physiological properties of aP vaccine components remains
incomplete, a critical shortfall in attempts to decide how best to
prevent pertussis in the future.
In accordance with its role as a virulence factor, in vivo studies
have shown that FHA is required for infection and persistence in
the lower respiratory tracts of mice, rats, and pigs by Bordetella
bronchiseptica (2, 6, 12–15), a close relative of B. pertussis that
naturally infects a broad range of mammalian hosts. Many Borde-
tella virulence factors, including FHA, are highly conserved and
have been shown to be functionally interchangeable between
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B. pertussis and B. bronchiseptica in animal models of disease (13,
16, 17). For these reasons, we use B. bronchiseptica infection of
common laboratory animals to assess the contribution of Borde-
tella virulence factors to pathogenesis. In addition to its postulated
role as an adhesin (18), FHA appears to perform immunomodu-
latory functions that contribute to colonization and/or persis-
tence (6, 12), though whether these effects are a direct result of
some undefined FHA activity (19–23) or an indirect result of
FHA-mediated adherence to specific host cells (6, 24, 25) is un-
clear.
FHA serves as a paradigm for TPS. FHA (defined as the ~250-
kDa protein that is both surface associated and released from the
bacterial surface) is initially translated as a preproprotein called
FhaB (~370 kDa), which contains an N-terminal signal peptide
and a large C-terminal “prodomain” that are removed during the
secretion process (a general diagram of the domain structure is
shown in Fig. S1 in the supplemental material). As with most
processed proteins, the “mature” molecule (~250-kDa FHA, in
this case) has been assumed to be the functional form of the pro-
tein. According to the current model of FHA secretion (26), the
signal peptide directs FhaB across the inner membrane via the Sec
translocation machinery (27) and is then removed by leader pep-
tidase. The ~250-amino-acid (aa) region of FhaB immediately C
terminal to the signal peptide, which is referred to as the TPS
domain and which is highly conserved among TpsA proteins, is
bound by chaperones that maintain the protein in a nonfolded
state as it transits through the periplasm (28, 29). FhaB then tran-
sits through FhaC in an N- to C-terminal direction, with the N
terminus remaining anchored to FhaC at the cell membrane (14,
26). The TPS domain initiates folding of FhaB into a rigid -helix
on the surface of the bacterium (30, 31), and progressive folding
results in formation of an ~50-nm-long shaft. C terminal to the
-helical shaft, an ~500-aa globular domain begins to fold into the
mature C-terminal domain (MCD) at the distal end of the mole-
cule (14, 32), which mediates adherence of the bacteria to host
cells in vitro and to respiratory epithelium in vivo (13, 26). Upon
translocation of the residues composing the MCD, the proximal
region of the FhaB prodomain (called the prodomain N terminus
[PNT]), which is conserved among FhaB-like TpsA proteins, pro-
hibits further translocation and retains the prodomain in an in-
tracellular compartment (26). We hypothesize that anchoring of
the C terminus of the MCD near the membrane by the PNT acts as
a sort of intramolecular chaperone that restricts the conforma-
tions that the MCD can sample during folding (26). Deletion of
the prodomain abrogates the ability of B. bronchiseptica to adhere
to host cells in vitro and to colonize the lower respiratory tracts of
mice and rats in vivo (14, 26), presumably due to misfolding of
the MCD.
Subsequent to translocation and folding of the MCD, proteol-
ysis of the FhaB C-terminal prodomain occurs by the activity of an
as-yet-unidentified protease(s) (14, 26). Degradation is rapid and
complete (14, 26, 33), making it unlikely that the prodomain per-
forms an independent function. In PNT strains, in which the
prodomain is aberrantly translocated to the surface, the prodo-
main is readily detected (26), indicating that the prodomain is not
intrinsically unstable but is instead subject to regulated degrada-
tion inside the cell. Production of FhaB molecules lacking the
C-terminal half of the MCD results in detectable, stable intracel-
lular prodomain polypeptides (26), further supporting the hy-
pothesis of regulated degradation and indicating a role for the
extracellular MCD in this regulation. Additional processing to
form the C terminus of mature FHA occurs and is dependent on
the surface-localized serine protease autotransporter SphB1 (34).
Although the primary function attributed to FHA is adherence to
respiratory epithelium, FHA is ultimately released from the cell
surface, liberating FhaC to secrete another FhaB molecule.
While adherence is the primary function attributed to FHA,
our previous observations suggest that portions of the FhaB
prodomain contribute to additional virulence activities mediated
by FHA. For example, small deletions near the C terminus of the
prodomain abrogated persistent tracheal infection of rats by
B. bronchiseptica, though adherence capabilities in vitro were pre-
served (14). Here, we set out to determine the contribution of two
C-terminal FhaB subdomains, a proline-rich region (PRR) and a
conserved extreme C terminus (ECT), to FhaB/FHA function. We
also investigated how prodomain degradation is controlled and
what role its regulation plays in the maturation and function
of FHA.
RESULTS
The FhaB prodomain localizes to the periplasm. Previous studies
demonstrated that the PNT is necessary for retention of the FhaB
prodomain in an intracellular compartment, which is essential for
proper folding and function of FHA (26). To determine if the C
terminus of the prodomain enters the periplasm or if it remains in
the cytoplasm, we created a B. bronchiseptica strain containing a
fusion of phoA (lacking the codons for its natural signal peptide)
to the 3= end of fhaB. Note that all mutations described in this
study were made in a derivative of B. bronchiseptica strain RB50
lacking fhaS (RBX11) to facilitate genetic manipulation of fhaB
and interpretation of FhaB maturation data (35). fhaS is a gene
displaying high nucleotide sequence similarity to fhaB in B. bron-
chiseptica. However, deletion of fhaS does not produce any detect-
able effects on B. bronchiseptica pathogenicity in animal models
(35), and we refer to RBX11 as the wild-type (WT) strain in this
study. PhoA activity, assayed by conversion of the chromogenic
substrate 5-bromo-4-chloro-3-indolyl phosphate (X-P) to a blue
product, is observed only when PhoA is present in the periplasm
(36). Western blot analysis of whole-cell lysates (WCL) and cul-
ture supernatants of the WT strain producing the fusion protein
displayed no changes in the amount of FhaB or FHA (FhaB/FHA)
produced, processed, or released (Fig. 1a), indicating that fusion
of PhoA to the C terminus of FhaB did not alter FhaB secretion.
We also performed dot blot analysis of the strain producing FhaB
with the C-terminal PhoA fusion, probing the blots with an
-MCD antibody (and with a secondary antibody with green flu-
orescence) and an -PhoA antibody (and with a secondary anti-
body with red fluorescence). As seen previously (26), the MCD
was detected on the surface of intact bacteria and in disrupted cells
(Fig. 1b). In contrast, PhoA was detected only in disrupted cells,
indicating that the prodomain remained intracellular. Culture of
this strain on plates containing X-P resulted in growth of blue
colonies (Fig. 1c), which, combined with the fact that proteins are
secreted through the Sec translocon in an N-to-C-terminal fash-
ion (37), indicates that the entire FhaB prodomain is transported
to the periplasm during secretion and therefore that the periplasm
is the compartment in which prodomain functions occur.
The ECT of FhaB negatively regulates prodomain degrada-
tion, while the PRR plays no apparent role in FhaB/FHA pro-
cessing. Western blot analysis of WT B. bronchiseptica revealed the
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presence of ~370-kDa FhaB preproprotein and multiple pro-
cessed FHA proteins of ~250 kDa in whole-cell lysates (WCL) and
processed ~250-kDa FHA proteins only in culture supernatants
(Fig. 2). The largest processed polypeptide is referred to as FHA=
in B. bronchiseptica (FHA* in B. pertussis) and is produced via
degradation of the prodomain by an unidentified protease(s) (14,
34). The most abundant processed polypeptide is referred to as
FHA and is produced in an SphB1-dependent manner via cleavage
of FhaB or FHA= (14, 34). Two smaller processed polypeptides,
which are similar in size and often comigrate on SDS-PAGE gels,
are referred to as FHA1 and FHA2 and are also produced in an
SphB1-dependent manner. The SphB1-dependent FHA, FHA1,
and FHA2 proteins are the predominant forms released from the
bacterial surface, while FHA=/FHA* is primarily released only in
strains lacking SphB1, although a small amount can sometimes be
detected in culture supernatants of WT cells (14, 34).
The FhaB C terminus includes a proline-rich region (PRR) (26,
38) that is composed of 27% proline residues (as opposed to 2%
across the remainder of FhaB) and contains two conspicuous re-
peat motifs (see Fig. S1b in the supplemental material). Excluding
minor differences in the length or number of repeats, the pre-
dicted PRRs are 87% identical and 92% similar among the strains
of Bordetella spp. that cause disease in the mammals for which
genome sequence information is available. C terminal to the PRR
are 98 aa (see Fig. S1c) that are 100% identical among all predicted
FhaB proteins, which we refer to here as the FhaB extreme C ter-
minus (ECT). Western blot analysis of a strain producing FhaB
that lacks both subdomains (PRR-ECT) revealed the absence of
full-length FhaB in WCL (Fig. 2), but a lack of these subdomains
had no discernible effect on the amount of FHA produced or
released into the culture medium. Deletion of sphB1 in the PRR-
ECT strain resulted in detection of a doublet that included FHA=
and a slightly smaller polypeptide that we had not observed pre-
viously but which was present also in culture supernatants of the
WT strain (Fig. 2).
To investigate the contribution of the individual C-terminal
subdomains to FhaB processing, we constructed B. bronchiseptica
strains that produced FhaB proteins lacking either the PRR or the
ECT. Similarly to the PRR-ECT strain, no full-length FhaB was
detected by Western blot analysis of the ECT strain (Fig. 2).
Deletion of sphB1 in the strain lacking the ECT resulted in detec-
FIG 1 The FhaB prodomain transits to the periplasm, where it is retained
during secretion. (a) Western blot analysis of whole-cell lysates (WCL) and
culture supernatants (Sup.) from strains containing 3= fusions of phoA to fhaB.
C-terminal PhoA fusion (CT-PhoA strains) did not alter production or pro-
cessing of FhaB or release of FHA. Membranes were probed as described for
panel b. (b) Dot blot analysis of intact (not boiled) and disrupted (boiled)
bacteria for strains not producing PhoA (WT) or with PhoA fused to the C
terminus of FhaB (CT-PhoA strains). Membranes were probed with -MCD
(green) and -PhoA (red) antibodies, and the green and red channels are
overlaid. PhoA was accessible to antibodies only after lysis of the cells by boil-
ing. (c) Culture of strains containing various phoA insertions on an agar plate
containing a chromogenic PhoA substrate. Fusion of PhoA (lacking its native
signal peptide) to the C terminus of FhaB (CT-PhoA strains) resulted in pro-
duction of blue colonies similar to those produced by a strain constitutively
producing PhoA (WT PhoA), while strains constitutively producing PhoA
lacking its native signal peptide (WT SP-PhoA) or not producing PhoA
(WT) did not produce blue colonies.
FIG 2 The extreme C terminus (ECT) of the FhaB prodomain inhibits prodo-
main degradation. Results of Western blot analysis of whole-cell lysates (WCL)
and culture supernatants (Sup.) from strains lacking the FhaB PRR (PRR) or
the FhaB ECT (ECT) or both (PRR-ECT) or neither (WT), as well as each
strain lacking sphB1, are shown. Strains lacking the FhaB ECT did not contain
any observable FhaB in the WCL or Sup. fractions. Membranes were probed
with -MCD antibodies. The FhaB molecules translated by each strain are
diagrammed at the top of the figure (dark blue, signal peptide; pink, TPS
domain; purple, -helical domain; green, MCD; brown, PNT; light blue, un-
characterized prodomain; red, PRR; yellow, ECT).
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tion of only FHA= and the slightly smaller polypeptide (Fig. 2).
Western blot analysis of a strain containing an HA epitope inser-
tion 7 aa N terminal to the FhaB C terminus also abolished detec-
tion of full-length FhaB (see Fig. S3 in the supplemental material)
(26), suggesting that the reason for the strict conservation of the
ECT in Bordetella cells is that this functional element is unable to
tolerate mutation. Additionally, SphB1-dependent processing still
occurred in the ECT strain (Fig. 2), indicating that FhaB reaches
the surface during secretion. These results indicate that the ECT is
a negative regulator of prodomain degradation; without it, the
prodomain is degraded aberrantly quickly such that full-length
FhaB cannot be detected. Additionally, stable prodomain frag-
ments were not detected in WCL (see Fig. S2), indicating that
prodomain removed from FhaB in the ECT strain is degraded
rapidly, as it is in the parental strain.
Western blot analysis of WCL and culture supernatants of the
PRR strain, in contrast, displayed no difference in the amount of
FhaB/FHA produced, processed, or released compared with WT
bacteria (Fig. 2). This finding suggests that the PRR does not play
a role in FhaB processing. Additionally, fusion of PhoA to the C
terminus of FhaB in the strain lacking the PRR resulted in blue
colonies (Fig. 1c), while Western blot analysis of WCL and culture
supernatants of the PRR strain producing the fusion protein
displayed no changes in the amount of FhaB/FHA produced, pro-
cessed, or released (Fig. 1a). These results indicate that the PRR
does not influence prodomain transport to the periplasm. To test
whether the PRR is involved in retention of the prodomain in the
periplasm, we performed a dot blot analysis. Similar to the WT
strain results, the MCD was detected on the surface of intact bac-
teria and in disrupted cells and PhoA was detected only in dis-
rupted cells (Fig. 1b), indicating that the prodomain remained
intracellular and that the PRR does not contribute to intracellular
retention of the prodomain. Furthermore, deletion of the PRR did
not result in increased proportions of full-length FhaB in WCL
samples or release of full-length FhaB into culture supernatants in
a sphB1 strain (Fig. 2), as is seen with strains lacking the PNT
(26). SphB1-dependent processing still occurs in the PRR strain
(Fig. 2), suggesting that FhaB reaches the surface during secretion.
Together, these results suggest that the PRR does not play a role in
production of mature FHA.
Mature FHA is sufficient to mediate adherence to respiratory
epithelium. Since the ECT strain essentially produces only ma-
ture FHA, this strain provided a tool to investigate whether ma-
ture FHA is indeed the active form of the protein in vivo. Because
in vitro adherence assays are typically performed with nonciliated,
nonpolarized cell lines and Bordetella cells adhere primarily to
ciliated respiratory epithelium in vivo (39, 40), we developed an in
vivo assay to assess the contribution of FHA to adherence to the
respiratory tract (41). Using this protocol, ~1% of the inoculum of
WT bacteria was recovered in bronchoalveolar lavage fluid
(BALF), indicating that ~99% of the bacteria were retained in the
respiratory tract. In contrast, ~27% of the inoculum was recov-
ered for an avirulent Bvg-negative (Bvg) phase-locked strain that
is completely nonadherent in vitro (Fig. 3) (42). Thus, ~30% re-
covery appears to be the upper limit of detection in this assay for
nonadherent strains. Inoculation with a FHA-null strain resulted
in recovery of ~30% of the inoculum in the BALF (Fig. 3), indi-
cating that FHA is an essential adhesin for B. bronchiseptica in the
murine respiratory tract.
To determine whether the accelerated degradation of the
prodomain in strains lacking the C-terminal subdomains of FhaB
alters adherence of B. bronchiseptica in vivo, we inoculated mice
with strains lacking the PRR, the ECT, or both. Approximately 2%
of the inoculum of the PRR-ECT strain was recovered in the
BALF (Fig. 3), indicating that the C-terminal subdomains are not
required for FHA-mediated adherence in vivo. Accordingly, ~2%
FIG 3 Properly folded FHA is necessary and sufficient for adherence of
B. bronchiseptica to the respiratory tract. (a) CFU recovered in BALF 30 to
60 min after intranasal inoculation of mice. Each point represents the number
of CFU recovered from a single animal. (b) Recovery of bacteria in BALF
represented as the percentage of the inoculum for each strain. Only strains
lacking a properly folded MCD displayed decreased retention in the murine
respiratory tract. The FhaB molecules translated by each strain are dia-
grammed at the top of the figure (dark blue, signal peptide; pink, TPS domain;
purple, -helical domain; green, MCD; brown, PNT; light blue, uncharacter-
ized prodomain; red, PRR; yellow, ECT). Data are pooled from 2 separate
experiments conducted on different days. Percentages of inoculum data are
represented as means  standard errors of the means (SEM). ***, P  0.001.
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of the inoculum of the ECT strain and ~4% of the inoculum of
the PRR strain were recovered in the BALF (Fig. 3). These find-
ings reveal that mature FHA is sufficient to mediate adherence to
the respiratory tract. Additionally, coinoculation of WT B. bron-
chiseptica with the PRR strain, the ECT strain, or the FHA-null
strain did not alter recovery of each strain compared to inocula-
tion with each strain alone (Fig. 3). These results indicate that in
vivo adherence is determined on a per-bacterium basis and that
FHA proteins secreted by WT bacteria are unable to complement
adherence defects.
Deletion of a large portion of the FhaB prodomain (including
most of the PNT) was previously demonstrated to abrogate
B. bronchiseptica adherence to rat lung epithelial L2 cells and
B. pertussis adherence to human lung epithelial A549 cells in vitro
(14, 26). This mutation also resulted in aberrant folding of the
FHA MCD (26). Furthermore, -MCD antibodies were able to
abrogate adherence of B. pertussis and B. bronchiseptica to both rat
lung epithelial L2 cells and mouse macrophage-like J774A.1 cells
in vitro (13). Together, these findings suggest that the MCD facil-
itates FHA-mediated adherence and that the FhaB prodomain is
required for correct folding of the MCD. In agreement with these
findings, ~24% of the inoculum of a B. bronchiseptica
Prodomain strain was recovered in the BALF (Fig. 3). Consid-
ered together with the result that deletion of the C-terminal sub-
domains did not abrogate FHA-mediated adherence to the respi-
ratory tract, these findings support the requirement of an intact
PNT to mediate retention of the prodomain, which facilitates
folding of the MCD, and to produce a FHA molecule capable of
mediating adherence to the respiratory tract. Combined, these
data further suggest that FHA is folded correctly and is able to
confer adherence capabilities to B. bronchiseptica in strains lacking
the ECT. Since the PRR does not influence FhaB/FHA processing
(Fig. 2) or FhaB prodomain localization (Fig. 1), these data also
strongly suggest that the PRR does not play a role in production of
functional mature FHA. The mature FHA molecules produced in
the PRR and ECT strains are thus indistinguishable from those
produced by WT bacteria, and therefore the only difference be-
tween the WT and mutant strains is the full-length FhaB mole-
cules they produce.
Mature FHA is not sufficient for B. bronchiseptica persis-
tence in the lower respiratory tract. Deletion of both the PRR and
ECT subdomains (PRR-ECT) was previously shown to reduce
persistence in the tracheas of rats (14), even though this strain is
capable of adhering both in vivo (Fig. 3) and in vitro (14). To
determine which of the individual C-terminal subdomains is in-
volved in FhaB/FHA-mediated virulence activities, we inoculated
mice intranasally with various B. bronchiseptica strains and mon-
itored bacterial burden in the respiratory tract over time. As has
been observed previously (6, 12, 13), WT bacteria persisted at high
levels in the trachea and lungs through 11 days postinoculation,
and FHA-null bacteria were mostly cleared from the trachea and
lungs by 11 days postinoculation (Fig. 4a). The FHA-null strain
displayed an increase in burden at 1 day postinoculation com-
pared to WT bacteria, a bimodal distribution of burden at 3 days
postinoculation, and a dramatic reduction in burden by day 11
(Fig. 4a). Additionally, as has been previously shown (2, 12–14),
the number of CFU recovered from the nasal cavity for the FHA-
null strain was similar to that for WT bacteria (see Fig. S4 in the
supplemental material), indicating that FHA is not required for
colonization and persistence in the upper respiratory tract of ro-
dents.
Similarly to the FHA-null strain, the ECT strain was unable to
persist in the murine lower respiratory tract, as most mice had
FIG 4 The FhaB proline-rich region and extreme C terminus are necessary
for B. bronchiseptica persistence in the lower respiratory tract in a manner that
is distinct from suppression of inflammation. (a) Bacterial burden in the mu-
rine lower respiratory tract after intranasal inoculation. Each point represents
the number of CFU recovered from a single animal. Open symbols represent
the lower limit of detection for that particular experiment, as no CFU were
recovered. (b) Production of proinflammatory cytokines (IL-1) and chemo-
kines (KC, MCP-1) in the murine lung during infection. Cytokine and chemo-
kine levels were determined from lung homogenates by ELISA. Data represent
means  SEM of the results determined for all samples, which were collected
from all animals for which CFU are shown in Fig. 4a. Data are pooled from 2
separate experiments conducted on different days. PI, postinfection. *, P 
0.05; **, P  0.01; ***, P  0.001.
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completely cleared this strain from their trachea and lungs by
11 days postinoculation (Fig. 4a). However, the course of infec-
tion of the ECT strain differed from that of the FHA-null strain;
there was no increase in burden at 1 day postinoculation and no
bimodal burden distribution at 3 days postinoculation in the
lungs (Fig. 4a). The PRR strain also displayed increased clear-
ance from the mouse trachea and lungs compared to WT bacteria
(Fig. 4a), whereas, similarly to the results seen with the FHA-null
bacteria, colonization and persistence in the nasal cavity were not
compromised (see Fig. S4 in the supplemental material). We also
created the identical PRR mutation in WT strain RB50, which
contains an intact fhaS gene, and deletion of the PRR in this back-
ground resulted in the same persistence defect in the lower respi-
ratory tract (see Fig. S5), demonstrating that the decreased persis-
tence in the lower respiratory tract is due to the lack of the FhaB
PRR rather than to the lack of fhaS (in addition to the PRR
mutation) or an undetected additional mutation elsewhere on the
chromosome. Since the mature FHA molecules produced by the
PRR strain and the ECT strain are indistinguishable from those
produced by WT bacteria, these results indicate that the presence
of mature FHA is not sufficient to mediate B. bronchiseptica per-
sistence, revealing an active role for the full-length FhaB polypep-
tide in vivo that is dependent on both the PRR and the ECT.
Mature FHA is sufficient for immunomodulation. Previous
studies have suggested that FHA contributes to Bordetella persis-
tence in mice via suppression of inflammation (6, 12). To ascer-
tain whether the increased clearance observed with our PRR and
ECT strains is due to an increased induction of inflammation
compared to WT bacteria, we measured global cytokine and
chemokine levels in the mouse lung during infection. As previ-
ously reported (6), the FHA-null strain induced higher produc-
tion of proinflammatory cytokines, such as interleukin-1 (IL-
1), and chemokines, such as the neutrophil chemoattractant KC
and monocyte chemoattractant protein-1 (MCP-1), than WT
bacteria (Fig. 4b). There was no difference in global levels of
gamma interferon (IFN-), tumor necrosis factor  (TNF-), IL-
10, IL-12p70, IL-17, IL-22, or IL-23 produced in the lungs of mice
infected with WT or FHA-null bacteria (see Fig. S6 in the supple-
mental material), suggesting that the primary difference in the
innate immune response to infection with WT or FHA-null bac-
teria is the intensity of the initial IL-1-mediated inflammation.
In contrast to FHA-null bacteria, neither the ECT strain nor
the PRR strain stimulated higher inflammatory cytokine or
chemokine production than the WT strain during infection
(Fig. 4b). These data suggest that the increased clearance observed
with these strains is not due to a lack of FHA-mediated immuno-
suppression and that mature FHA is sufficient to suppress the
initial inflammatory response.
Full-length FhaB is required for resistance to early-immune-
response-mediated clearance. We previously demonstrated that
coinoculation of mice with WT and FHA-null bacteria partially
“rescues” persistence of FHA-null bacteria in the lungs compared
to inoculation with only the FHA-null strain, while the persistence
of WT bacteria after coinoculation was unaltered compared to
inoculation with only the WT strain (12). Inflammation was sup-
pressed after coinoculation compared to inoculation with only
FHA-null bacteria; however, FHA-null bacteria were still not able
to persist as well as WT bacteria (12), suggesting that FhaB/FHA
may mediate resistance to clearance even under less-
inflammatory conditions. Similarly to those previous findings, the
number of CFU of WT bacteria recovered after coinoculation with
the FHA-null strain was unchanged compared to the number re-
covered after inoculation with only WT bacteria, while the num-
ber of CFU of the FHA-null bacteria was increased compared to
the number seen after inoculation with only FHA-null bacteria at
11 days postinoculation (Fig. 4 and 5a). Additionally, production
of proinflammatory IL-1 and KC after coinoculation was iden-
tical to that seen in mice inoculated with only WT bacteria
(Fig. 5b). However, the number of CFU of the FHA-null strain at
11 days postinoculation in the coinoculation experiment was still
lower than that of WT bacteria, supporting the hypothesis that
FhaB/FHA plays another role in persistence that is distinct from its
role in suppressing the intensity of the inflammatory response.
In contrast to coinoculation of mice with WT and FHA-null
bacteria, coinoculation of WT bacteria with either the ECT or
PRR strain did not alter clearance of the mutant bacteria; they
were cleared as rapidly as when inoculated in the absence of WT
bacteria (Fig. 5a). Production of cytokines and chemokines was
similarly unaltered during coinoculation compared to inocula-
tion with only WT bacteria (Fig. 5b). Since WT bacteria failed to
“rescue” either the ECT or PRR strain in the presence of an
unaltered inflammatory response, these results support the hy-
pothesis that the virulence defect of the ECT and PRR strains
that leads to the decreased persistence is a lack of resistance to
clearance by the early immune response. Moreover, these results
strongly argue that mature FHA is not sufficient for this activity,
revealing a functional role for premature FhaB in resistance to
innate immunity-mediated clearance and indicating that the PRR
is essential for that activity.
DISCUSSION
Our previous studies revealed that FhaB secretion and maturation
are highly regulated activities. The conserved N-terminal region of
the prodomain is required for proper MCD folding and subse-
quent adherence capabilities (26). Additionally, we observed pro-
duction of stable intracellular prodomain fragments in strains
lacking the C-terminal portion of the MCD (26), suggesting a role
for the MCD in regulating prodomain degradation. Together,
these findings indicated that information is relayed bidirectionally
across the outer membrane via the FhaB primary sequence (i.e.,
regulation of MCD folding on the bacterial surface and initiation
of prodomain degradation in the periplasm). Here, we deter-
mined that the prodomain resides in the periplasm during FhaB
secretion (Fig. 1) and demonstrated that deletion of the FhaB ECT
resulted in the inability to detect full-length FhaB molecules
(Fig. 2), indicating that the ECT is a negative regulator of prodo-
main degradation in the periplasm. A model of FhaB secretion
taking these findings into account is shown in Fig. S7 in the sup-
plemental material.
Taking advantage of the fact that the ECT strain essentially
produces only mature FHA, we examined whether FHA was in
fact capable of performing all virulence functions that have been
attributed to this molecule. Using our recently developed in vivo
adherence assay (41), we found that FHA is both necessary and
sufficient to mediate adherence to the murine respiratory tract
(Fig. 3). Additionally, the ECT strain was capable of suppressing
the acute inflammatory response in the murine lower respiratory
tract (Fig. 4b), indicating that mature FHA is also both necessary
and sufficient to perform this function. Surprisingly, however, the
ECT strain was unable to persist in the murine lower respiratory
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tract (Fig. 4a), and coinfection with WT bacteria did not rescue the
persistence defect or alter the inflammatory response (Fig. 5).
These data reveal three previously unappreciated aspects of FHA
physiology: (i) the persistence defect of FHA-mutant strains is not
due solely to lack of adherence or suppression of inflammation,
(ii) mature FHA is not sufficient to facilitate all fhaB-mediated
virulence activities, and (iii) full-length FhaB is therefore required
for resistance to innate immune effectors. In support of these con-
clusions, deletion of the FhaB PRR, which did not result in any
FhaB secretion abnormalities (Fig. 1 and 2) or affect production of
functional mature FHA (Fig. 3 and 4b), produced phenotypes
almost identical to those seen with the ECT strain, indicating
that the defect for both these strains is the lack of functional full-
length FhaB molecules and that the PRR is essential for FhaB ac-
tivity.
We hypothesize that transmission of information is the basis
for the activity of full-length FhaB, acting as a transmembrane
sensor, and that the PRR is integral for relaying information in
vivo. Due to the fact that it contains repeat motifs (see Fig. S1b in
the supplemental material) and to the proclivity of polyproline
peptides to adopt an extended conformation (43), we postulate
that the PRR acts as a docking site for protein interactions in the
periplasm and that modulation of these interactions is required
for resisting the early immune response. These interactions likely
direct the action of a short-range effector(s), as the defects ob-
served with the PRR and ECT strains appeared to operate on a
per-bacterium basis (Fig. 3 and 5). Discriminating between the
potential mechanisms by which this occurs will be the subject of
future investigations. We expect that the defect in B. bronchiseptica
lower respiratory tract persistence observed for the PRR strain is
due to decreased resistance to clearance by phagocytes. While de-
creased resistance to other aspects of the innate immune response
is possible, it is unlikely that full-length FhaB is necessary for re-
sistance to mechanical clearance, as the PRR and ECT strains
displayed normal adherence to the respiratory tract (Fig. 3) or to
secreted molecular immune effectors. Additionally, while we can-
not rule out a role for early adaptive immunity in clearance of the
mutant strains from the lower respiratory tract between days 3 and
11 (Fig. 4), we expect that any involvement of antibody-mediated
clearance would be through opsonization as a means for uptake by
phagocytes. In contrast, FhaB/FHA has been reported to mediate
interactions with phagocytes (44–46).
Our results suggest that the mature form of FHA is not suffi-
cient to mediate resistance to clearance by the early immune re-
sponse. This finding perhaps elucidates a paradox in FHA physi-
ology, namely, that FHA, a critical adhesin, is released from the
bacterial surface in large quantities (Fig. 2). While our experi-
ments were unable to determine whether released FHA plays a role
in suppression of the immune response, as has been suggested
(19–23), this work provides a description of an alternative role for
release of FHA. FHA release may predominantly serve the purpose
of liberating FhaC to secrete a new FhaB molecule, which can then
mediate persistence in the lower respiratory tract. If true, this hy-
pothesis suggests that the multiple processing events that FhaB
undergoes serve several purposes. Initiation of prodomain degra-
dation may serve as the periplasmic signal that FhaB has sensed
environmental changes, while SphB1-dependent cleavage, which
results in increased release of FHA from the surface (Fig. 2) (14,
34), may facilitate FhaB turnover.
Integral to understanding the physiological function of pro-
FIG 5 The persistence defect of the PRR and ECT strains cannot be
rescued by WT bacteria. (a) Bacterial burden in the murine lower respiratory
tract after coinoculation with WT and FHA mutant strains marked with dif-
ferent antibiotic resistance genes. Each point represents the number of CFU
recovered from a single animal. Open symbols represent the lower limit of
detection for that particular experiment, as no CFU were recovered. (b) Pro-
duction of proinflammatory cytokines (IL-1) and chemokines (KC, MCP-1)
in the murine lung during coinfection. Cytokine and chemokine levels were
determined from lung homogenates by ELISA. Data represent means  SEM
of the results determined for all samples, which were collected from all animals
for which CFU are shown in Fig. 5a. Data are pooled from the results of 2
separate experiments conducted on different days. Statistical significance is
indicated for mutant bacteria compared to the WT strain from the same coi-
noculation group. *, P  0.05; **, P  0.01; ***, P  0.001.
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teins is elucidation of the means by which they achieve their func-
tional forms. For processed proteins, it is typically assumed that
the final polypeptide observed in vitro is the functional form of the
protein. This work suggests that precursor molecules are impor-
tant to the physiological function of some processed proteins. The
results presented here demonstrate the presence of multiple intra-
molecular determinants of FhaB prodomain degradation, in ad-
dition to multiple known intermolecular determinants, indicating
that “maturation” of FhaB is a tightly regulated process. While
dysregulation of prodomain degradation does not affect the abil-
ity of mature FHA to mediate adherence or immunosuppression
during infection (Fig. 3 and 4b), these studies yielded the unex-
pected finding that full-length FhaB plays an active role in patho-
genesis, specifically in resisting clearance by innate immune effec-
tors. Our results highlight the advantage of studying protein
secretion and function simultaneously, as a role for the FhaB PRR
was evident only from in vivo infection studies and not from stud-
ies on the production or maturation of FHA or even from
virulence-associated in vitro assays (14). Our results also provide a
reminder that, while culturing bacteria in the laboratory is ex-
tremely useful and often essential for understanding the molecu-
lar mechanisms underlying microbiological processes such as pro-
tein secretion, in vitro growth conditions may not accurately
mimic the conditions under which the microbiological processes
under study function in nature.
MATERIALS AND METHODS
Bioinformatics. Protein sequences were obtained from the NCBI Protein
Database. Sequence alignments were conducted using Clustal Omega (47)
and visualized using Jalview Version 2 (48). Searches for similar sequences
were conducted with BLASTp.
Ethics statements. This study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory
Animals of the NIH. Our protocols were approved by the University of
North Carolina IACUC (10-134, 12-307, and 13-238). All animals were
properly anesthetized for inoculations, monitored regularly, and eutha-
nized when moribund, and efforts were made to minimize suffering.
Growth media and bacterial strains. B. bronchiseptica strains were
grown at 37°C in Stainer-Scholte (SS) broth or on Difco Bordet-Gengou
(BG) agar (BD) supplemented with 5.5% defibrinated sheep blood (Col-
orado Serum Co., Denver, CO). Escherichia coli strains were grown at
37°C in Luria broth (LB) or on LB agar. A detailed description of bacterial
strains, their construction, and the rationale for their use is included in
Methods in Text S1 in the supplemental material. Where appropriate,
media were supplemented with gentamicin (30 g/ml), streptomycin
(20 g/ml), kanamycin (50 g/ml), MgSO4 (50 mM), diaminopimelic
acid (200 g/ml), or 5-bromo-4-chloro-3-indolyl phosphate (XP;
40 g/ml).
Immunoblotting. To evaluate FHA production and processing, pro-
teins were prepared from B. bronchiseptica cultures grown in SS broth and
normalized based on optical density. For cell-associated proteins, whole-
cell lysates (WCL) of bacteria were prepared by boiling in sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer.
For released proteins, culture supernatants precipitated with 10% trichlo-
roacetic acid (TCA; Fisher Scientific) were mixed with SDS-PAGE sample
buffer and boiled. Proteins were separated by SDS-PAGE on 5% poly-
acrylamide gels, transferred to nitrocellulose (GE Healthcare), and
probed with a rabbit polyclonal antibody generated against the FHA ma-
ture C-terminal domain (MCD) (13), a mouse monoclonal antibody gen-
erated against PhoA (Covance), or a mouse monoclonal antibody gener-
ated against an HA epitope (Covance). Corresponding -rabbit and
-mouse IRDye secondary antibodies were used to detect proteins (Li-
COR Biosciences). Membranes were imaged on a Li-COR Odyssey Classic
infrared Imager (Li-COR Biosciences).
To assess the surface accessibility of proteins, B. bronchiseptica cells
grown in SS broth were washed and resuspended in phosphate-buffered
saline (PBS; Life Technologies), and half of each sample was boiled to
disrupt the cells. Intact and disrupted cells were then spotted on nitrocel-
lulose and probed with a rabbit polyclonal -MCD antibody and a mouse
monoclonal -PhoA antibody. Corresponding -rabbit and -mouse
IRDye secondary antibodies were used to detect proteins, and membranes
were imaged on an Li-COR Odyssey Classic infrared Imager.
Bacterial adherence to the respiratory tract. Bacterial adherence was
measured using a recently developed in vivo adherence assay (41). Briefly,
6-week-old female BALB/cJ mice from Jackson Laboratories (Bar Harbor,
ME) were anesthetized with isoflurane and inoculated intranasally with
7.5  104 CFU (CFU) of B. bronchiseptica–50 l PBS. For coinoculation
experiments, WT and mutant strains were marked with different antibi-
otic resistance genes as described in Methods in Text S1 in the supple-
mental material. Mice were euthanized 30 to 60 min after inoculation.
Bronchoalveolar lavage fluid (BALF) was collected by inserting a cannula
into the trachea, ligating with a suture, and injecting and retracting 1 ml
PBS. Serial dilutions of BALF and the inoculum were plated on BG agar to
quantitate recovery of bacterial CFU.
Bacterial persistence and characterization of the immune response
during infection of mice. Six-week-old female BALB/cJ mice were inoc-
ulated and euthanized as described above. For coinoculation experiments,
WT and mutant strains were marked with different antibiotic resistance
genes as described in Methods in Text S1 in the supplemental material.
Lungs, tracheas, and nasal cavities were harvested and homogenized in
PBS. Serial dilutions of homogenized tissues were plated on BG agar (with
appropriate antibiotics) to quantitate recovery of bacterial CFU. Cytokine
production and chemokine production were analyzed by conducting
enzyme-linked immunosorbent assays (ELISA) on lung homogenates di-
luted in PBS (R&D Systems).
Statistical analysis. Data were plotted and statistical analyses were
performed using Prism version 5.0 software (GraphPad Software, Inc.).
For all conditions analyzed, at least six experiments (two or more separate
experiments on different days with n  3) were performed, and statistical
significance was determined using analysis of variance (ANOVA).
SUPPLEMENTAL MATERIAL
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